peptides that work FAQ

Start VIP analog administration 2–4 weeks post-injury, once acute swelling has resolved but before chronic inflammatory cascades establish a maladaptive baseline. Research from the University of Pittsburgh found maximal symptom reduction when VIP protocols began in this subacute window. Starting earlier risks interference with the brain's natural acute-phase immune response, while waiting beyond 8 weeks means working against entrenched neuroinflammatory tone. Subcutaneous administration at 300–400 mcg three times weekly for 8–12 weeks is the standard observational protocol.

VIP and growth hormone pathways are complementary, not redundant. Growth hormone secretagogues like MK 677 elevate IGF-1, which supports neuronal survival and myelin integrity. Mechanisms VIP doesn't directly address. Combining VIP analogs (2–3× weekly) with MK 677 (daily at 12.5–25 mg) produces additive neuroprotective effects in observational settings. Monitor fasting glucose if using both long-term, as IGF-1 elevation can impair insulin sensitivity in susceptible individuals.

VIP's neuroprotective mechanism doesn't produce stimulant-like subjective effects. It works through long-term reduction of oxidative stress and restoration of synaptic health. Measurable improvement typically emerges at 6–10 weeks when assessed via objective cognitive testing (digit span, trail-making tests, memory recall tasks), not through day-to-day subjective energy or focus. If cognitive testing at 8 weeks shows no improvement, review reconstitution protocol, verify peptide purity via third-party analysis, and confirm you're not using counterproductive compounds (alcohol, chronic NSAIDs) that blunt the anti-inflammatory signal.

If lyophilised peptide powder arrives at room temperature but the vial seal is intact and the powder appears dry (not clumped or discolored), refrigerate it immediately at 2–8°C and reconstitute within 48 hours. Most peptides tolerate brief temperature excursions up to 25°C for 24–48 hours if they remain in lyophilised form. Once reconstituted, discard any solution that wasn't stored continuously at refrigeration temperature. Aqueous peptides degrade rapidly above 8°C.

No. Cloudiness in reconstituted peptide solution indicates aggregation. Irreversible clumping of peptide molecules caused by temperature exposure, contamination, or improper pH during reconstitution. Aggregated peptides lose receptor affinity and may trigger immune responses if used in vivo. Discard cloudy solutions immediately. Properly reconstituted peptides should be clear to slightly opalescent with no visible particles. Store bacteriostatic water at 2–8°C before mixing to minimise aggregation risk.

For most research applications, 96% purity is acceptable if the remaining 4% consists of salts or buffer components rather than peptide fragments or synthesis by-products. Review the HPLC chromatogram: if impurity peaks appear at retention times close to the main peptide peak, they're likely deletion sequences or truncated analogs that may interfere with receptor binding. If impurities elute far from the peptide peak, they're typically residual solvents or salts that don't affect biological activity. When in doubt, request a mass spec report to identify the impurities by molecular weight.